Promises and challenges of translational research in neuropsychiatry

Translational Neuroscience: Applications in Psychiatry, Neurology, and Neurodevelopmental Disorders

Volumn , Issue , 2012, Pages 339-358

  Braff, David L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84925614879     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511980053.021     Document Type: Chapter

References (104)

1. Adler LE, Hoffer LD, Wiser A, Freedman R. 1993. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 150:1856–1861.
2. Bleuler E. 1911. Dementia praecox, oder Gruppe der Schizophrenien. Leipzig: F. Deuticke.
3. Blondeau K, Boecxstaens V, Van Oudenhove L et al. 2011. Increasing body weight enhances prevalence and proximal extent of reflux in GERD patients ‘on’ and ‘off’ PPI therapy. Neurogastroenterol Motil 23:724–e327.
4. Bloom J, Hinrichs AL, Wang JC. 2011. The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans. Pharmacogenet Genomics 21:403–416.
5. Braff DL. 2010. Prepulse inhibition of the startle reflex: a window on the brain in schizophrenia. Curr Top Behav Neurosci 4:349–371.
6. Braff DL. 2011. Gating in schizophrenia: from genes to cognition (to real world function?). Biol Psychiatry 69:395–396.
7. Braff DL, Beck AT. 1974. Thinking disorder in depression. Arch Gen Psychiatry 31:456–459.
8. Braff DL, Freedman R. 2008. Clinically responsible genetic testing in neuropsychiatric patients: a bridge too far and too soon. Am J Psychiatry 165:952–955.
9. Braff DL, Freedman R, Schork NJ, Gottesman II. 2007a. Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. Schizophr Bull 33:21–32.
10. Braff DL, Geyer MA, Swerdlow NR. 2001. Human studies of prepulse inhibition of startle: Normal subjects, patient groups, and pharmacological studies. Psychopharmacology 156:234–258.
11. Braff DL, Greenwood TA, Swerdlow NR et al. 2008. Advances in endophenotyping schizophrenia. World Psychiatry 7:11–18.
12. Braff DL, Schork NJ, Gottesman II. 2007b. Endophenotyping schizophrenia. Am J Psychiatry 164:705–707.
13. Brennard KJ, Simone A, Jou J et al. 2011. Modelling schizophrenia using human induced pluripotent stem cells. Nature 473:221–225.
14. Britton C. 1938. The Anatomy of Revolution. New York, NY: Random House.
15. Caballero RJ. 2010. Macroeconomics after the crisis: time to deal with the pretense-of-knowledge syndrome. J Econ Perspectives 24:85–102.
16. Callard F, Rose D, Wykes T. 2011. Close to the bench as well as at the bedside: involving service users in all phases of translational research. Health Expect May 25. doi: 10.1111/j.1369–7625.2011.00681.x. [Epub ahead of print].
17. Cannon TD, Keller MC. 2006. Endophenotypes in the genetic analyses of mental disorders. Annu Rev Clin Psychol 2:267–290.
18. Carter CS, Barch DM, Bullmore E et al. 2011. Cognitive neuroscience treatment research to improve cognition in schizophrenia II: developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders. Biol Psychiatry 70:7–12.
19. Chou HH, Chiu HC, Delaney NF, Segre D, Marx CJ. 2011. Diminishing returns epistasis among beneficial mutations decelerates adaptation. Science 333:1190–1192.
20. Collins FS. 2009. The Language of Life: DNA and the Revolution in Personalized Medicine. New York, NY: Harper Collins Publishers.
21. Durnaoglu S, Genc S, Genc K. 2011. Patient-specific pluripotent stem cells in neurological diseases. StemCells Int 2011:212-487. Epub 2011 Jul 3.
22. Eickhoff SB, Bzdok D, Laird AR. 2011. Co-activation patterns distinguish cortical modules, their connectivity and functional differentiation. Neuroimage 57:938–949.
23. Feigin A. 1998. Advances in Huntington’s disease: implications for experimental therapeutics. Curr Opin Neurol 11:357–362.
24. Francis DD, Szegda K, Campbell G, Martin WD, Insel TR. 2003. Epigenetic sources of behavioral differences in mice. Nat Neurosci 6:445–446.
25. Freathy RM, Kazeem GR, Morris RW et al. 2011. Genetic variation at CHRNA5-CHRNA3-CHRNB4 interacts with smoking status to influence body mass index. Int J Epidemiol [Epub ahead of print, May 18].
26. Gaab N, Gabrieli JD, Deutsch GK, Tallal P, Temple E. 2007. Neural correlates of rapid auditory processing are disrupted in children with developmental dyslexia and ameliorated with training: an fMRI study. Restor Neurol Neurosci 25:295–310.
27. GAIN Collaborative Research Group, Manolio TA, Rodriguez LL. 2007. New models of collaboration in genome-wide association studies: the Genetic Association Information Network. Nat Genet 39:1045–1051.
28. Gamaleddin I, Wertheim C, Zhu AZ et al. 2011. Cannabinoid receptor stimulation increases motivation for nicotine and nicotine seeking. Addict Biol Apr 26. doi:10.1111/j.1369-1600.2011.00314.x. [Epub ahead of print].
29. Gamaleddin I, Guranda M, Goldberg SR, Lefoll B. 2011. The selective anandamide transport inhibitor VDM11 attenuates reinstatement of nicotine seeking induced by nicotine associated cues and nicotine priming, but does not affect nicotine-intake. Br J Pharmacol Apr 18. doi:10.1111/j.1476-5381.2011.01440.x. [Epub ahead of print].
30. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR. 2001. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156:117–154.
31. Gibson G. 2010. Hints of hidden heritability in GWAS. Nat Genet 42:558–560.
32. Goldstein JL, Brown MS. 2008. From fatty streak to fatty liver: 33 years of joint publications in the JCI. J Clin Invest 118:1220–1222.
33. Gottesman II, Gould TD. 2003. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 160:636–645.
34. Granger BB, Bosworth HB. 2011. Medication adherence: emerging use of technology. Curr Opin Cardiol 26:279–287.
35. Greenwood TA, Braff DL, Light GA et al. 2007. Initial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. Arch Gen Psychiatry 64:1242–1250.
36. Greenwood TA, Lazzeroni LC, Murray SS et al. 2011.Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry [Epub ahead of print, Apr 15]
37. Grillon C, Courchesne E, Ameli R, Geyer MA, Braff DL. 1990. Increased distractibility in schizophrenic patients. Electrophysiologic and behavioral evidence. Arch Gen Psychiatry 47:171–179.
38. Gur RC, Ragland JD, Moberg PJ et al. 2001. Computerized neurocognitive scanning: II. The profile of schizophrenia. Neuropsychopharmacology 25:777–788.
39. Hallmayer J, Cleveland S, Torres A et al. 2011. Genetic heritability and shared environmental factors among twin pairs with autism. Arch Gen Psychiatry [Epub ahead of print, Jul 4].
40. Hansen T, Ingason A, Djurovic S et al. 2011. At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia. Biol Psychiatry 70:59–63.
41. Hazlett EA, Buchsbaum MS, Tang CY et al. 2001. Thalamic activation during an attention-to-prepulse startle modification paradigm: a functional MRI study. Biol Psychiatry 50:281–291.
42. Helfand M, Tunis S, Whitlock EP et al. 2011.ACTSA agenda to advance methods for comparative effectiveness research. Clin Transl Sci 4:188–198.
43. Ho LW, Carmichael J, Swartz J et al. 2001. The molecular biology of Huntington’s disease. Psychol Med 31:3–14.
44. Ibrahim HM, Tamminga CA. 2011. Schizophrenia: treatment targets beyond monoamine systems. Annu Rev Pharmacol Toxicol 51:189–209.
45. Insel TR, Collins FS. 2003. Psychiatry in the genomics era. Am J Psychiatry 160:616–620.
46. Insel T, Cuthbert B, GraveyMet al. 2010. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry 167:748–751.
47. Insel TR, Lehner T. 2007. A new era in psychiatric genetics? Biol Psychiatry 61:1017–1018.
48. King MC, Weiand S, Hale K et al. 2001. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABPP1) Breast Cancer Prevention Trial. J Am Med Assoc 286:2251–2256.
49. Klein DF. 2008. The loss of serendipity in psychopharmacology. J Am Med Assoc 299:1063–1065.
50. Kolata G. 2011. How bright promise in cancer testing fell apart. New York Times, July 7.
51. Kraepelin E. 1971. Dementia Praecox and Paraphrenia. Huntington, NY: RE Krieger Publishing Company. Lazzeroni LC, Ray A. 2010. The cost of large numbers of hypothesis tests on power, effect size and sample size. Mol Psychiatry [Epub ahead of print, Nov. 9].
52. Licinio J, Wong ML. 2004. Translational research in psychiatry: pitfalls and opportunities for career development. Mol Psychiatry 9:117.
53. Loughead J, Ray R, Wileyto EP et al. 2011. Brain activity and emotional processing in smokers treated with varenicline. Addict Biol Apr 20. doi:10.1111/j.1369-1600. [Epub ahead of print].
54. Markou A, Chiamulera C, Geyer MA, Tricklebank M, Steckler, T. 2009. Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacol Rev 34: 74–89.
55. McGhie A, Chapman J. 1961. Disorders of attention and perception in early schizophrenia. Br J Med Psychol 34:103–116.
56. McKinney WT. 1984. Animal models of depression: an overview. Psychiatr Dev 2:77–96.
57. Moskvina V, Cradock N, Muller- Myhsok B et al. 2011. An examination of single nucleotide polymorphism selection prioritization strategies for tests of gene–gene interaction. Biol Psychiatry 70:198–203.
58. Nakaoka H, Inoue I. 2009. Meta-analysis of genetic association studies: methodologies, betweenstudy heterogeneity and winner’s curse. J Hum Genet 54:615–623.
59. National Center for Research Resources. 2011. NCRR Fact Sheet. Clinical and Translational Science Awards. Bethesda, MD: National Center for Research Resources. Available at: http://www.ctsaweb. org/docs/CTSA_FactSheet.pdf. [Accessed September 7, 2011].
60. Nestler EJ, Hyman SE. 2010. Animal models of neuropsychiatric disorders. Nat Neurosci 13:1161–1169.
61. Ott J, Wang J. 2011.Multiple phenotypes in genome-wide genetic mapping studies. Protein Cell 2:519–522.
62. Owen MJ, Craddock N, O’Donovan MC. 2010. Suggestion of roles for both common and rare risk variants in genome-wide studies of schizophrenia. Arch Gen Psychiatry 67:667–673.
63. Pander J, Gelderblom H, Guchelaar HJ. 2007. Insights into the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anticancer drugs. Expert Opin Pharmacother 8:1197–1210.
64. Parr LA. 2011. The evolution of face processing in primates. Trans R Soc Lond B Biol Sci 366:1764–77.
65. Paul SM. 2011. Therapeutic antibodies for brain disorders. Sci Transl Med 3:84ps20.
66. Pedrosa E, Sandler V, Shah A et al. 2011. Development of patientspecific neurons in schizophrenia using induced pluripotent stem cells. J Neurogenet [Epub ahead of print, July 29].
67. Pincus HA. 2011. Academic health centers and comparative effectiveness research: baggage, buckets, basics, and bottles. Acad Med 86:659–660.
68. Platt JR. 1964. Strong inference: certain systematic methods of scientific thinking may produce much more rapid progress than others. Science 146:347–353.
69. Popov T, Jordanov T, Rockstroh B et al. 2011. Specific cognitive training normalizes auditory sensory gating in schizophrenia randomized trial. Biol Psychiatry 69:465–471.
70. Post RM. 2007. Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neurosci Biobehav Rev 31:858–873.
71. Preskorn SH. 2010. CNS drug development: Part I: The early period of CNS drugs. J Psychiatr Res 16:334–339.
72. Quednow BB, Ettinger U, Mössner R et al. 2011. The schizophrenia risk allele C of the TCF4 rs9960767 polymorphism disrupts sensorimotor gating in schizophrenia spectrum and healthy volunteers. J Neurosci 31:6684– 6691.
73. Ray R, Ruparel K, Newberg A et al. 2011. Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proc Natl Acad Sci USA 108:9268–9273.
74. Reglodi D, Kiss P, Lubics A, Tamas A. 2011. Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo. Curr Pharm Des 17:962–972.
75. Saxena S, Gorbis E, O’Neill J et al. 2009. Rapid effects of brief intensive cognitive-behavioral therapy on brain glucose metabolism in obsessive-compulsive disorder. Mol Psychiatry 14:197–205.
76. Scherma M, Justinová Z, Zanettini C et al. 2011. The anandamide transport inhibitor AM404 reduces the rewarding effects of nicotine and nicotine-induced dopamine elevations in the nucleus accumbens shell in rats. Br J Pharmacol May 9. doi:10.1111/j.1476-5381.2011.01467.x. [Epub ahead of print].
77. Schwartz JM, Stoessel PW, Baxter Jr, LR, Martin KM, Phelps ME. 1996. Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive–compulsive disorder. Arch Gen Psychiatry 53:109–113.
78. Selker HP. 2010. Beyond translational research from T1 to T4: Beyond “separate but equal” to integration (Ti). Clin Transl Sci 3:270–271.
79. Selker HP, Califf RM. 2011. The need for academic leadership in fullspectrum translational research. Clin Transl Sci 4:78–79.
80. Shoulson I, Young AB. 2011. Milestones in Huntington disease. Mov Disord 26:1127–1133.
81. Siegel SJ. 2011. What can we expect from long-acting formulations for schizophrenia? Curr Psychiatry Rep 13:243–244.
82. Sim K, Lee J, Subramaniam M et al. 2011. Integrated genetic and genomic approach in the Singapore Translational and Clinical Research in Psychosis Study: an overview. Early Interv Psychiatry 5:91–99.
83. So H-C, Gui AHS, Cherny SS, Sham PC. 2011. Evaluating the heritability explained by known susceptibility variants: a survey of ten complex diseases. Gen Epidemiol 35:310–317.
84. Soldner F, Laganiere J, Cheng AW et al. 2011. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 146:318–331.
85. Sung NS, Crowley WF Jr, Genel M et al. 2003. Central challenges facing the national clinical research enterprise. J Am Med Assoc 289:1278–1287.
86. Swerdlow NR. 2010. Integrative circuit models and their implications for the pathophysiologies and treatments of the schizophrenias. Curr Top Behav Neurosci 4:555–583.
87. Swerdlow NR. 2011. Are we studying and treating schizophrenia correctly? Schizophr Res 130:1–10.
88. Swerdlow NR, Geyer MA, Braff DL. 2001. Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology (Berl) 156:194–215.
89. Swerdlow NR, Koob GF. 1987. Lesions of the dorsomedial nucleus of the thalamus, medial prefrontal cortex and pedunculopontine nucleus: effects on locomotor activity mediated by nucleus accumbensventral pallidal circuitry. Brain Res 412:233–243.
90. Swerdlow NR, Light GA, Cadenhead KC et al. 2006. Startle gating deficits in a large cohort of patients with schizophrenia: relations, medications, symptoms, neurocognition, and level of function. Arch Gen Psychiatry 63:1325–1335.
91. Swerdlow NR, Weber M, Qu Y, Light GA, Braff DL. 2008. Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology (Berl) 199:331–388.
92. Teipel SJ, Buchert R, Thome J, Hampel H, Pahnke J. 2011. Development of Alzheimer-disease neuroimagingbiomarkers using mouse models with amyloid-precursor proteintransgene expression. Prog Neurobiol [Epub ahead of print, May 12].
93. Thorne GL, Dawson ME, Schell AM. 2005. Attention and prepulse inhibition: the effects of taskrelevant, irrelevant, and no-task conditions. Int J Psychophysiol 56:121–128.
94. Tao J, Wu H, Lin Q et al. 2011. Deletion of astroglial Dicer causes non-cell-autonomous neuronal dysfunction and degeneration. J Neurosci 31:8306–8319.
95. Tuma RS. 2010. Duke scandal shines light on systemic problems in high-throughput experiments. Oncology Times 32:13–15.
96. Vacic V, McCarthy S, Malhotra D et al. 2011. Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia. Nature 471:499–503.
97. Visscher PM, Goddard ME, Derks EM, Wray NR. 2011. Evidence-based psychiatric genetics, AKA the false dichotomy between common and rare variant hypotheses. Mol Psychiatry June 14. doi:10.1038/mp.2011.65. [Epub ahead of print].
98. Walsh T, McClellan JM, McCarthy SE et al. 2008. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 320:539–543.
99. Watson JD, Crick FHC. 1953. Molecular structure of nucleic acids: a structure for deoxyribose nucleic acid. Nature 171:737–738.
100. Weissman MM. 2007. Cognitive therapy and interpersonal psychotherapy: 30 years later. Am J Psychiatry 164:693–696.
101. Weissman MM, Brown AS, Talati A. 2011. Translational epidemiology in psychiatry: linking population to clinical and basic sciences. Arch Gen Psychiatry 68:600–608.
102. Wu AH, Wang P, Smith A et al. 2008. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics 9:169–178.
103. Yang J, Benyamin B, McEvoy BP et al. 2010. Common SNPs explain a large proportion of the heritability for human height. Nat Genet 42:565–569.
104. Zammit S, Owen MJ, Lewis G. 2010. Misconceptions about gene–environment interactions in psychiatry. Evid Based Ment Health 13:65–68.